academyX officially launches as a new advanced training programme for neurologists specialising in myasthenia gravis. The initiative has been designed and established by SDA Bocconi School of Management in collaboration with argenx, with a specific focus on neuromuscular diseases and myasthenia gravis.

The partnership between SDA Bocconi and argenx is grounded in a shared commitment to fostering advanced capabilities in a highly complex therapeutic area, where scientific and technological innovation increasingly requires a deep understanding of how healthcare systems function and evolve.

At a time when neurological conditions pose significant epidemiological, clinical and economic challenges, academyX aims to contribute to the development of specialists who combine clinical excellence with a strong ability to interpret organisational, decision-making and sustainability dynamics within healthcare systems.

“AcademyX was created to offer neurologists a training programme that integrates clinical and managerial competencies,” explains Monica Otto, Scientific Director of the programme and Director of Executive Education for Government, Health and Not for Profit at SDA Bocconi. “The programme has been designed to support participants in understanding the organisational and decision-making mechanisms of healthcare systems, promoting a multidisciplinary approach to the management of neuromuscular diseases and myasthenia gravis.”

The programme, endorsed by the Italian Society of Neurology (SIN), will involve approximately 25 neurologists specialising in myasthenia gravis and will be delivered throughout 2026.

AcademyX adopts a multidisciplinary, value-based educational model that brings together clinical and management perspectives to strengthen healthcare system governance capabilities. The programme integrates advanced clinical content on neuromuscular diseases and myasthenia gravis with key themes such as healthcare system governance, pharmaceutical policy, clinical research, the assessment of clinical and economic evidence, and the evolving role of digital health and artificial intelligence in neurological practice.

“Neurology today represents a complex challenge, for which purely clinical training is no longer sufficient,” notes Raffaele Iorio, neurologist at Fondazione Policlinico Universitario Agostino Gemelli IRCCS and Scientific Lead of the project. “Understanding how healthcare systems operate and how access to therapies is regulated is essential to helping develop care pathways that are both sustainable and equitable.”

“The management of myasthenia gravis increasingly requires close integration between clinical practice, therapeutic innovation and new technologies,” adds Lorenzo Maggi, neurologist at Fondazione IRCCS Istituto Neurologico Carlo Besta and Scientific Lead of the project. “Bringing together medicine, data and technology means improving continuity of care and personalising treatments throughout the patient journey.”

“As a company strongly focused on innovation in neurological diseases,” concludes Fabrizio Celia, Managing Director of argenx Italy, “we feel a responsibility to help improve patients’ quality of life also through initiatives such as academyX, which promote high-level education for the benefit of patients and the National Health System.”

SDA Bocconi further strengthens its commitment to developing innovative educational models that combine scientific rigour, managerial capabilities and leadership, in support of the evolution of healthcare systems and patient-centred care.

SDA Bocconi School of Management